164 related articles for article (PubMed ID: 36758570)
1. Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial.
Borup C; Vinter-Jensen L; Jørgensen SPG; Wildt S; Graff J; Gregersen T; Zaremba A; Borup Andersen T; Nøjgaard C; Timm HB; Rainteau D; Hansen SH; Rumessen JJ; Munck LK
Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):321-331. PubMed ID: 36758570
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial.
Kårhus ML; Brønden A; Forman JL; Haaber A; Knudsen E; Langholz E; Dragsted LO; Hansen SH; Krakauer M; Vilsbøll T; Sonne DP; Knop FK
Lancet Gastroenterol Hepatol; 2022 Oct; 7(10):922-931. PubMed ID: 35868334
[TBL] [Abstract][Full Text] [Related]
3. Prospective comparison of diagnostic tests for bile acid diarrhoea.
Borup C; Vinter-Jensen L; Jørgensen SPG; Wildt S; Graff J; Gregersen T; Zaremba A; Andersen TB; Nøjgaard C; Timm HB; Lamazière A; Rainteau D; Hansen SH; Rumessen JJ; Munck LK
Aliment Pharmacol Ther; 2024 Jan; 59(1):39-50. PubMed ID: 37794830
[TBL] [Abstract][Full Text] [Related]
4. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome.
Camilleri M; Acosta A; Busciglio I; Boldingh A; Dyer RB; Zinsmeister AR; Lueke A; Gray A; Donato LJ
Aliment Pharmacol Ther; 2015 Mar; 41(5):438-48. PubMed ID: 25594801
[TBL] [Abstract][Full Text] [Related]
5. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
[TBL] [Abstract][Full Text] [Related]
6. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.
Riemsma R; Al M; Corro Ramos I; Deshpande SN; Armstrong N; Lee YC; Ryder S; Noake C; Krol M; Oppe M; Kleijnen J; Severens H
Health Technol Assess; 2013 Dec; 17(61):1-236. PubMed ID: 24351663
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
8. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
[TBL] [Abstract][Full Text] [Related]
9. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
[TBL] [Abstract][Full Text] [Related]
10. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study.
Beigel F; Teich N; Howaldt S; Lammert F; Maul J; Breiteneicher S; Rust C; Göke B; Brand S; Ochsenkühn T
J Crohns Colitis; 2014 Nov; 8(11):1471-9. PubMed ID: 24953836
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial.
Vijayvargiya P; Camilleri M; Carlson P; Nair A; Nord SL; Ryks M; Rhoten D; Burton D; Busciglio I; Lueke A; Harmsen WS; Donato LJ
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2962-2970.e6. PubMed ID: 32088296
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
Johnsen PH; Hilpüsch F; Cavanagh JP; Leikanger IS; Kolstad C; Valle PC; Goll R
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):17-24. PubMed ID: 29100842
[TBL] [Abstract][Full Text] [Related]
15. Review article: bile acid diarrhoea - pathogenesis, diagnosis and management.
Mottacki N; Simrén M; Bajor A
Aliment Pharmacol Ther; 2016 Apr; 43(8):884-898. PubMed ID: 26913381
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention.
Pattni SS; Brydon WG; Dew T; Johnston IM; Nolan JD; Srinivas M; Basumani P; Bardhan KD; Walters JR
Aliment Pharmacol Ther; 2013 Oct; 38(8):967-76. PubMed ID: 23981126
[TBL] [Abstract][Full Text] [Related]
17.
Mena Bares LM; Carmona Asenjo E; García Sánchez MV; Moreno Ortega E; Maza Muret FR; Guiote Moreno MV; Santos Bueno AM; Iglesias Flores E; Benítez Cantero JM; Vallejo Casas JA
Rev Esp Med Nucl Imagen Mol; 2017; 36(1):37-47. PubMed ID: 27765536
[TBL] [Abstract][Full Text] [Related]
18. Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption.
Kårhus ML; Brønden A; Lyng Forman J; Haaber A; Vilsbøll T; Sonne DP; Knop FKK
BMJ Open; 2021 Feb; 11(2):e044711. PubMed ID: 33558360
[TBL] [Abstract][Full Text] [Related]
19. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: colestyramine vs. hydroxypropyl cellulose in patients with functional chronic watery diarrhoea.
Fernández-Bañares F; Rosinach M; Piqueras M; Ruiz-Cerulla A; Modolell I; Zabana Y; Guardiola J; Esteve M
Aliment Pharmacol Ther; 2015 Jun; 41(11):1132-40. PubMed ID: 25858478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
